Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
245
resultados
Última actualización
14/08/2025 [06:52:00]
Resultados 75 a 100 de 245
Resumen de: US2025250227A1
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and the use thereof in the formulation of a lipid nanoparticle for delivering an active ingredient. The present disclosure also relates to a composition containing the amino lipid compound, and in particular relates to a lipid nanoparticle and the use thereof.
Resumen de: US2025248937A1
The invention provides novel compositions of fluorocarbon nanoemulsions comprising one or more of fluorosurfactants and phospholipids, and methods of preparation and use thereof for enhanced oxygen delivery.
Resumen de: US2025249099A1
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Resumen de: US2025249123A1
Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Resumen de: US2025249122A1
The subject matter disclosed herein is directed to nitric oxide releasing particles comprising a mesoporous silica network. Also disclosed are compositions comprising one or more nitric-oxide releasing particles and a polymer. In one aspect, the particles are admixed with the polymer. The compositions exhibit high payloads of nitric oxide release without particle leaching or the need for extremely cold storage conditions.
Resumen de: US2025249059A1
Disclosed herein are a non-bee made honey formulations comprising fructose in an amount from about 20% to about 55% w/w; glucose in an amount from about 20% to about 40% w/w; one or organic acids in an amount from about 0.001% to about 5% w/w; water; and one of the following: one or more polyphenols in a concentration of at least 0.4 mM; or a total antioxidant capacity of at least 1,500 nM/uL Trolox Equivalents. In some embodiments, the total antioxidant capacity is at least that of natural bee-made clover honey. In some embodiments, the total antioxidant capacity exceeds that of natural bee-made clover honey.
Resumen de: CN119899265A
The present invention describes single domain monoclonal antibodies that specifically bind to B7H3 (also known as CD276). The single-domain monoclonal antibody comprises a camel VHH domain nano antibody and a rabbit VH domain nano antibody which are selected from a phage display library. B7H3-targeted chimeric antigen receptors (CARs) and other antibody conjugates are also described. The single-domain monoclonal antibody and the conjugate thereof can be used for diagnosing and treating solid tumors expressing B7H3.
Resumen de: US2025249062A1
Provided is a use of dipsaci radix-derived extracellular vesicle-like nanoparticles (DREVNs) in preparation of a drug for preventing or treating orthopedic diseases. In this application, EVs are creatively extracted from dipsaci radix and purified, and the physiological efficacy of the EVs is studied. It has been found that the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs), can promote the osteogenic differentiation of BMSCs by activating a BMP2/Smads signaling pathway, promote the calcified nodule formation in BMSCs, and promote the expression of osteogenic differentiation-associated genes ALP, OCN, RUNX2, and COL1, and have bone targetability in vivo. The EVs can be intragastrically administered to alleviate the osteoporosis (OP) in postmenopausal mice. Therefore, the EVs have the potential of being used to prepare drugs for preventing or treating orthopedic diseases, and provide a new strategy for the prevention or treatment of orthopedic diseases.
Resumen de: US2025248928A1
Nanoparticles and nanoparticle-releasing vaginal rings for intermediate- to long-term delivery of drugs to the female genital and reproductive tract have been developed. The nanoparticles are loaded with drugs and coated with a sheddable poly(ethylene glycol) (PEG) layer that promotes mucus penetration and then converts to an adhesive form after penetration. This platform technology readily distributes drug through the mucosa and throughout the vaginal tissue, enhances local retention of drugs within the vaginal tissue, thereby providing a sustained delivery of drugs beyond the natural shedding and turnover of vaginal mucous and epithelial cells.
Resumen de: US2025248926A1
Prolonged delivery of chemodrugs locally inside the brain with sufficient tissue-penetration is a critical requirement for treating various brain-diseases including malignant tumors. The present disclosure relates to an injectable microparticle system for brain-drug delivery. The injectable microparticle system comprising drug-loaded polymeric microparticles, wherein the drug-loaded polymeric microparticles are coated with an outer polymer gel layer enabling in-situ formation and releasing drug-polymer nanocomplexes of size <100 nm. The injectable microparticle system facilitates both deep tissue penetration for >2 cm as well as ‘sustained release’ of the drug for 15-30 days. The invention also discloses a method of producing said injectable microparticle system and the use of said injectable microparticle system in the treatment of brain tumor and other cancers.
Resumen de: US2025248939A1
Provided herein are, inter alia, nucleic acids, lipid nanoparticles, lipid nanoparticles comprising nucleic acids encapsulated therein, pharmaceutical compositions comprising lipid nanoparticles which comprise nucleic acids encapsulated therein, methods of treating diseases, such as cancer, and methods of delivering lipid nanoparticles to myeloid cells, lymphoid organs, and tumors.
Resumen de: US2025248946A1
Methods and compositions for cellular rejuvenation of immune cells, such as T cells, are provided. Cellular rejuvenation can be achieved by exposure, such as transient exposure, of immune cells to mRNAs encoding reprogramming factors. Compositions comprising such rejuvenated immune cells, including rejuvenated T cells, and uses of the rejuvenated immune cells in treating certain diseases and/or disorders, such as cancer and immune disorders, are also provided
Resumen de: US2025248978A1
The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
Resumen de: US2025248997A1
The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Resumen de: US2025248945A1
The disclosure relates, in part, to biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoid compounds and compositions thereof. In certain embodiments, the LNPs selectively target a cell of interest (e.g., an immune cell, stem cell, bone cell, blood cell, fat cell, endothelial cell, cancer cell, tissue cell, nerve cell, epithelial cell, connective tissue cell, and muscle cell, inter alia). In certain embodiments, the disclosure further relates to methods for in vivo delivery of therapeutic agents for the treatment, prevention, and/or amelioration of diseases or disorders using the LNPs of the disclosure.
Resumen de: US2025248986A1
The present disclosure provides an antifungal drug inhalation formulation, comprising: crystalline nanoparticles of a triazole antifungal drug. The present disclosure further provides a preparation method and use of the antifungal drug inhalation formulation.
Resumen de: US2025250576A1
In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGFβ signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.
Resumen de: US2025250226A1
Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
Resumen de: US2025251396A1
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
Resumen de: AU2025205468A1
The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines. The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines. ul h e p r e s e n t i n v e n t i o n p r o v i d e s , a m o n g o t h e r t h i n g s , m e t h o d s a n d c o m p o s i t i o n s o f u l f o r m u l a t i n g n u c l e i c a c i d - c o n t a i n i n g n a n o p a r t i c l e s f o r e f f i c i e n t d e l i v e r y o f p a y l o a d i n v i v o s u c h t h a t t h e m e t h o d a n d c o m p o s i t i o n s c a n b e u s e d t o g e n e r a t e m v a c c i n e s
Resumen de: CN119947757A
The present invention relates to compositions that can deliver therapeutic molecules, such as nucleic acids, to mammalian cells and to human and animal bodies, and methods of making and using the same. The compositions of the invention are useful in the medical field, such as in the treatment of cancer and autoimmune diseases.
Resumen de: WO2025165878A1
The disclosure relates generally to compositions and methods for delivery of an agent, e.g., a therapeutic agent, such as a nucleic acid, to a target tissue or organ. More particularly, the disclosure relates to the use of plant viral capsid proteins, for example, protein complexes comprising plant viral capsid proteins, for delivering therapeutic agents, such as nucleic acids, to target tissues and organs.
Resumen de: EP4596531A1
An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of -NH-, -O-, -S-, and a single bond; X is independently selected from -NR<sup>1</sup>R<sup>2</sup> or a nitrogen-containing heteroaryl group; L<sup>1</sup> and L<sup>2</sup> are each independently selected from a group consisting of a C<sub>1</sub>-C<sub>10</sub> alkylene group, a C<sub>2</sub>-C<sub>10</sub> alkenylene group,; R<sup>1</sup> and R<sup>2</sup> are each independently selected from a group consisting of H, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> hydrocarbyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heterohydrocarbyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>20</sub> aryl group, and a substituted or unsubstituted C<sub>1</sub>-C<sub>20</sub> heteroaryl group; R<sup>3</sup> is a C<sub>5</sub>-C<sub>30</sub> alkyl group; R<sup>4</sup> is a C<sub>5</sub>-C<sub>30</sub> alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.
Resumen de: AU2023360513A1
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucleotides that self-assemble into an RNA complex during RNA synthesis in a one-step production. Therefore, no additional conjugation or synthesis processes are required.
Nº publicación: EP4593801A2 06/08/2025
Solicitante:
UNIV TEXAS [US]
Board of Regents, The University of Texas System
Resumen de: WO2024077034A2
Generally, the present disclosure is directed to compositions and methods of using the same. In some embodiments, a composition described herein comprises a nanoparticle, a plurality of nanofibers disposed on an exterior surface of the nanoparticle, and a payload disposed within an interior of the nanoparticle. The nanoparticle has an average size in three dimensions, and the plurality of nanofibers has an average length in a long dimension. In some cases, a ratio of the average size of the nanoparticle to the average length of the nanofibers is between 2 and 250.
BOPI
Sede Electrónica
